

Resource Summary Report

Generated by [dkNET](#) on Aug 16, 2026

Cyclin D1 Antibody

RRID:AB_2228523

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2922, RRID:AB_2228523

Antibody Information

URL: http://antibodyregistry.org/AB_2228523

Proper Citation: Cell Signaling Technology Cat# 2922, RRID:AB_2228523

Target Antigen: Cyclin D1

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10695719, AB_2228523.

Antibody Name: Cyclin D1 Antibody

Description: This unknown targets Cyclin D1

Target Organism: rat, mouse, human

Antibody ID: AB_2228523

Vendor: Cell Signaling Technology

Catalog Number: 2922

Record Creation Time: 20250820T030440+0000

Record Last Update: 20250820T151705+0000

Ratings and Alerts

- Used for western blot assay by the Human Islet Research Network community.
Contact(s): [Peng Wang](#), [Andrew Stewart](#) - Human Islets Research Network
<https://hirnetwork.org/>

No alerts have been found for Cyclin D1 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 40 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Ji F, et al. (2026) Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis. *Cell metabolism*, 38(4), 794.

Jiao J, et al. (2026) A new candidate tumor suppressor tRF-Ser inhibits gastric cancer progression by regulating the CNBP/HSPA8 axis. *Cell death & disease*, 17(1).

Zhang P, et al. (2026) SKA2 promotes gastric cancer progression by regulating glutathione metabolism. *iScience*, 29(4), 115202.

Liu F, et al. (2025) PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer. *Oncogene*, 44(33), 2997.

Guo Y, et al. (2025) Novel compounds with promising HuH-7 inhibitory activity as new cancer drug candidates: derivatives of N,N'-diphenylurea linked with 1,2,3-triazole. *Journal of enzyme inhibition and medicinal chemistry*, 40(1), 2585597.

Huang X, et al. (2025) CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma. *bioRxiv : the preprint server for biology*.

Xie M, et al. (2025) Tumor-resident probiotic *Clostridium butyricum* improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression. *Cancer cell*.

Samia U, et al. (2025) Effect of Soluble Factors Released from Porcine Freeze-Dried Lung Tissue (FDLT) on Modulation of Cell Growth and EMT Signature in Non-Small Cell Lung Cancer (NSCLC)-A Preliminary In Vitro Study. *International journal of molecular sciences*, 26(23).

Puleo N, et al. (2025) Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer. *Molecular cancer therapeutics*, 24(4), 639.

Li X, et al. (2025) SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer. *Journal of ovarian research*, 18(1), 167.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. *NPJ breast cancer*, 11(1), 135.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. *Cell reports*, 43(5), 114134.

Dimitrov J, et al. (2024) Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells. *Frontiers in immunology*, 15, 1470620.

Restaino AC, et al. (2024) Tumor-associated genetic amplifications impact extracellular vesicle miRNA cargo and their recruitment of nerves in head and neck cancer. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 38(13), e23803.

Yip HYK, et al. (2024) Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer. *NPJ precision oncology*, 8(1), 20.

Jacob JR, et al. (2024) miRNA-194-3p represses NF- κ B in gliomas to attenuate iPSC genes and proneural to mesenchymal transition. *iScience*, 27(1), 108650.

Lizardo MM, et al. (2024) Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(19), 4464.

Sun Y, et al. (2024) Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. *Cancer cell*, 42(8), 1386.

Zwirner S, et al. (2024) First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. *Cell*, 187(7), 1666.

Fu K, et al. (2024) *Streptococcus anginosus* promotes gastric inflammation, atrophy, and tumorigenesis in mice. *Cell*, 187(4), 882.